Corporate Overview
Pain Therapeutics is a biopharmaceutical company that develops novel drugs for pain management and hematology/oncology. We have three investigational drug candidates in clinical programs. Remoxy™ and PTI-202 are proprietary, abuse-deterrent forms of opioid drugs. Oxytrex™ is a novel, next-generation painkiller that potentially offers less physical dependence than currently marketed opioid painkillers. Our early-stage drugs include a novel radio-labeled monoclonal antibody to treat metastatic melanoma, a deadly form of skin cancer. We are also working on a new treatment for patients with hemophilia, a rare blood disorder. The FDA has not yet evaluated the merits, safety or efficacy of our drug candidates.
Pain Therapeutics Stock Information
| Current Price: |
$7.62 |
| Change |
+ 1.06%
0.08 |
| Day High |
$7.70 |
| Day Low |
$7.51 |
| Volume |
66,300 |
2:34 PM ET on Jul 3, 2008
Quote delayed at least 20 minutes.
|
|
Recent Releases
Jun 16, 2008
Pain Therapeutics Encouraged by Results of Melanoma Clinical Study
Jun 10, 2008
Pain Therapeutics and King Pharmaceuticals Announce Submission of New Drug Application for Remoxy
View all releases »
|
